Tolerance and Efficacy of Rituximab and Changes in Serum B Cell Biomarkers in Patients with Systemic Complications of Primary Sjögren's Syndrome

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Sep 5

PMID 16950808

Citations 71

Authors

Raphaele Seror

Christelle Sordet

Loic Guillevin

Eric Hachulla

Charles Masson

Marc Ittah

Sophie Candon

Veronique Le Guern

Achille Aouba

Jean Sibilia

Jacques-Eric Gottenberg

Xavier Mariette

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers.

Patients And Methods: The records of 16 patients with pSS according to the American European consensus group criteria were reviewed retrospectively.

Results: Patients, all women, had a median age of 58.5 (range 41-71) years and a disease duration of 9.5 (range 0-25) years. RTX was prescribed for lymphoma (n = 5), refractory pulmonary disease with polysynovitis (n = 2), severe polysynovitis (n = 2), mixed cryoglobulinaemia (n = 5), thrombocytopenia (n = 1) and mononeuritis multiplex (n = 1). The median follow-up duration was 14.5 (range 2-48) months. Three patients experienced adverse events, including one mild serum sickness-like reaction with the presence of human antichimeric antibodies. Efficacy of treatment was observed in 4 of 5 patients with lymphomas and in 9 of 11 patients with systemic involvement. Dryness was improved in only a minority of patients. Corticosteroid dose was reduced in 11 patients. RTX induced decreased rheumatoid factor, gamma-globulin and beta2-microglobulin levels, and the level of B cell activating factor of the tumour necrosis factor family (BAFF) increased concomitantly with B cell depletion. Five patients were re-treated, with good efficacy and tolerance, except for one with probable serum sickness-like reaction.

Conclusion: This study shows good efficacy and fair tolerance of RTX for systemic features. In addition, RTX allows for a marked reduction in corticosteroid use. Except for BAFF, the level of which increases, serum B cell biomarker levels decrease after taking RTX. Controlled trials should be performed to confirm the efficacy of RTX in pSS.

Citing Articles

The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series.

Sun M, Wang L, Liu X, Xiao F, Dai H Clin Kidney J. 2024; 17(8):sfae178.

PMID: 39119523 PMC: 11306976. DOI: 10.1093/ckj/sfae178.

Investigative biological therapies for primary Sjögren's syndrome.

He S, Xuan Y, Liang X, Guo K, Wang Y, Fu X Arch Med Sci. 2024; 20(2):506-516.

PMID: 38757038 PMC: 11094820. DOI: 10.5114/aoms.2020.97288.

Severe Headache in Primary Sjögren's Syndrome Responded to Rituximab.

Kudsi M, Haidar G, Hadid B, Roumieh E, Al-Sayed S Eur J Case Rep Intern Med. 2023; 10(10):004051.

PMID: 37789982 PMC: 10545156. DOI: 10.12890/2023_004051.

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance.

Marinho A, Delgado Alves J, Fortuna J, Faria R, Almeida I, Alves G Front Immunol. 2023; 14:1117699.

PMID: 37138867 PMC: 10150407. DOI: 10.3389/fimmu.2023.1117699.

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk.

Zingaropoli M, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A Biology (Basel). 2023; 12(4).

PMID: 37106787 PMC: 10135639. DOI: 10.3390/biology12040587.

References

DArcy C, Mannik M . Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001; 44(7):1717-8. DOI: 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C. View

Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B . Successful treatment of a patient with primary Sjögren's syndrome with Rituximab. Clin Rheumatol. 2005; 25(6):891-4. DOI: 10.1007/s10067-005-0086-0. View

Shih W, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D . F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med. 2002; 27(2):142-3. DOI: 10.1097/00003072-200202000-00019. View

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

Herishanu Y . Rituximab-induced serum sickness. Am J Hematol. 2002; 70(4):329. DOI: 10.1002/ajh.10127. View

Sansonno D, De Re V, Lauletta G, Tucci F, Boiocchi M, Dammacco F . Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2002; 101(10):3818-26. DOI: 10.1182/blood-2002-10-3162. View

Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G . Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003; 101(10):3827-34. DOI: 10.1182/blood-2002-09-2856. View

Somer B, Tsai D, Downs L, Weinstein B, Schuster S . Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003; 49(3):394-8. DOI: 10.1002/art.11109. View

Hansen A, Lipsky P, Dorner T . New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. Curr Opin Rheumatol. 2003; 15(5):563-70. DOI: 10.1097/00002281-200309000-00007. View

10.

Hellerstedt B, Ahmed A . Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 2003; 14(12):1792. DOI: 10.1093/annonc/mdg488. View

11.

Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X . Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol. 2004; 202(4):496-502. DOI: 10.1002/path.1533. View

12.

Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81. DOI: 10.1056/NEJMoa032534. View

13.

Beum P, Kennedy A, Taylor R . Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods. 2004; 289(1-2):97-109. DOI: 10.1016/j.jim.2004.03.012. View

14.

Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas A . Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology (Oxford). 2004; 43(8):1050-3. DOI: 10.1093/rheumatology/keh248. View

15.

Harner K, Jackson L, Drabick J . Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford). 2004; 43(10):1309-10. DOI: 10.1093/rheumatology/keh308. View

16.

Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, Cervera R, Font J . Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus. 2005; 13(12):969-71. DOI: 10.1191/0961203304lu2049xx. View

17.

Catuogno M, Rezai S, Priori R, Magrini L, Valesini G . Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford). 2005; 44(3):406. DOI: 10.1093/rheumatology/keh470. View

18.

Gottenberg J, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A . Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2004; 64(6):913-20. PMC: 1755517. DOI: 10.1136/ard.2004.029694. View

19.

Pijpe J, van Imhoff G, Vissink A, van der Wal J, Kluin P, Spijkervet F . Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis. 2004; 64(6):958-60. PMC: 1755505. DOI: 10.1136/ard.2004.030684. View

20.

Gottenberg J, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly R . Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. Ann Rheum Dis. 2005; 64(7):1050-5. PMC: 1755548. DOI: 10.1136/ard.2004.030643. View